Complete Genomics Cuts Wages, Other Costs as Financing Round is Delayed | GenomeWeb

NEW YORK (GenomeWeb News) - In response to a delay in the closing of its Series D financing round, Complete Genomics has cut its costs, including staff salaries, GenomeWeb Daily News sister publication In Sequence reported today.

According to Cliff Reid, the company's chairman, president, and CEO, the company is in the late stages of closing a Series D investment. But as a result of the slowdown of the capital markets in recent months, "it has taken us longer than anticipated to close," he said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.